Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERACYTE, INC.VCYT · Entity 2018 | Chief Scientific & Med Officer | December 06, 2022 | December 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERACYTE, INC.
Report date December 06, 2022 · Filed December 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,970 |
Reported balance
After 2022-12-06 transaction · row 1
1 source rowRow 1 · 2022-12-06 · Sale · Disposed 1,023 · Balance 65,970 F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 06, 2022 Filed Dec 8, 2022 22:18 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,023 | $27.03 | $27,651.69 |
DisclosureSEC source: 0001384101-22-000157 · wf-form4_167053791573091.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,970 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 22:19 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,008 | $29.14 | $29,373.12 |
DisclosureSEC source: 0001384101-22-000155 · wf-form4_167036513618601.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,993 F1 · kind: The reporting person is reporting the withholding of 248, 372, and 388 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 500, 750 and 781 Restricted Stock Units, respectively, granted on February 28, 2019, February 28, 2020 and February 26, 2021, respectively, and does not represent a sale by the reporting person. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 22:02 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 2 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001384101-22-000145 · wf-form4_166854970597951.xml · derivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 22:02 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2 | $29.34 | $58.68 |
DisclosureSEC source: 0001384101-22-000145 · wf-form4_166854970597951.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,001 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 22:02 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 2 | $14.34 | $28.68 |
DisclosureSEC source: 0001384101-22-000145 · wf-form4_166854970597951.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 22:44 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,023 | $25.00 | $25,575.00 |
DisclosureSEC source: 0001384101-22-000141 · wf-form4_166794747255272.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,001 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 20:57 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,008 | $19.18 | $19,333.44 |
DisclosureSEC source: 0001384101-22-000131 · wf-form4_166258421424158.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,024 F1 · kind: The reporting person is reporting the withholding of 248, 372, and 388 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 500, 750 and 781 Restricted Stock Units, respectively, granted on February 28, 2019, February 28, 2020 and February 26, 2021, respectively, and does not represent a sale by the reporting person. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 1 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · derivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 2 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · derivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 2 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2 shares Expires 2024-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 18,248 | $0.00 Strike: $27.90 | $0.00 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · derivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,248 Underlying: Common Stock · 18,248 shares Expires 2032-08-05 F3 · derivative.exercise_date: The option becomes exercisable as to 1/3rd of the shares on August 5, 2023, and the remaining shares vest at a rate of 1/36th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,028 | $26.54 | $27,283.12 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,032 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 1 | $5.43 | $5.43 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 2 | $6.45 | $12.90 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 2 | $10.45 | $20.90 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 10,702 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000113 · wf-form4_166007975334441.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,055 F1 · kind: Restricted stock units awarded on August 5, 2022 vest 1/3rd on September 2, 2023 and 1/12th per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 20:22 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 1,008 | $18.23 | $18,375.84 |
DisclosureSEC source: 0001384101-22-000074 · wf-form4_165454691147897.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,353 F1 · kind: The reporting person is reporting the withholding of 248, 372, and 388 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 500, 750 and 781 Restricted Stock Units, respectively, granted on February 28, 2019, February 28, 2020 and February 26, 2021, respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,407 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,407 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 100 | $26.49 | $2,649.00 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,391 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,844 | $25.70 | $150,189.05 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,491 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.41 to $26.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 17,059 | $24.91 | $424,944.81 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,335 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $24.40 to $25.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,407 | $5.98 | $26,353.86 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| March 04, 2022 Filed Mar 10, 2022 01:46 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,407 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,407 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F6 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 04, 2022 Filed Mar 10, 2022 01:46 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 100 | $26.49 | $2,649.00 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,361 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| March 04, 2022 Filed Mar 10, 2022 01:46 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,844 | $25.70 | $150,189.05 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,461 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.41 to $26.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2022 Filed Mar 10, 2022 01:46 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 17,089 | $24.91 | $425,697.24 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,305 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $24.40 to $25.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2022 Filed Mar 10, 2022 01:46 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,407 | $5.98 | $26,353.86 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 77,287 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · derivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,287 Underlying: Common Stock · 77,287 shares Expires 2032-03-03 F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2023, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 42,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000046 · wf-form4_164668883673823.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,987 F1 · kind: Restricted stock units awarded on March 3, 2022 vest 25% on March 2, 2023 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 03, 2022 Filed Mar 10, 2022 01:46 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 77,287 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · derivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,287 Underlying: Common Stock · 77,287 shares Expires 2032-03-03 F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2023, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2022 Filed Mar 10, 2022 01:46 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 42,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-22-000054 · wf-form4a_164687675656053.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,987 F1 · kind: Restricted stock units awarded on March 3, 2022 vest 25% on March 2, 2023 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:31 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 10,337 | $27.84 | $287,782.08 |
DisclosureSEC source: 0001384101-22-000040 · wf-form4_164643307661177.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,575 F1 · kind: The reporting person is reporting the withholding of 241, 173, 8,582, 260 and 1,081 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 588, 500, 24,000, 750 and 3,125 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019, February 28, 2019, February 28, 2020 and February 26, 2021 respectively, and does not represent a sale by the reporting person. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 1,750 | $26.55 Strike: $26.55 | $46,462.50 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · derivative · entry 13 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires 2030-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F8 · derivative.exercise_date: The option is fully vested. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,375 | $24.69 Strike: $24.69 | $108,018.75 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · derivative · entry 12 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,375 Underlying: Common Stock · 4,375 shares Expires 2030-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F7 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuousservice thereafter. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,750 | $41.55 | $72,712.50 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,912 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 4,375 | $39.69 | $173,643.75 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,662 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 1,750 | $26.55 | $46,462.50 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,375 | $24.69 | $108,018.75 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · derivative · entry 11 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 3,750 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,406 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · derivative · entry 10 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,407 Underlying: Common Stock · 4,406 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,785 | $37.26 | $66,509.81 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,912 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $36.88 to $37.66. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,897 | $36.11 | $140,709.37 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,697 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $35.79 to $36.74. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,550 | $35.37 | $125,564.92 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,594 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $34.70 to $35.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 3,750 | $20.21 | $75,787.50 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,406 | $5.98 | $26,347.88 |
DisclosureSEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 22:24 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 912 | $39.22 | $35,768.64 |
DisclosureSEC source: 0001384101-21-000176 · wf-form4_163882945893577.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,988 F1 · kind: The reporting person is reporting the withholding of 292, 248 and 372 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587, 500 and 750 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019 and February 28, 2020 respectively, and does not represent a sale by the reporting person. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 149 | $51.80 | $7,718.20 |
DisclosureSEC source: 0001384101-21-000161 · wf-form4_163597419799661.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,900 F1 · kind: The reporting person is reporting the withholding of 149 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 300 Restricted Stock Units, respectively, granted on May 11, 2020, and does not represent a sale by the reporting person. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 21:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 926 | $50.53 | $46,790.78 |
DisclosureSEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,049 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 4,375 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · derivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 4,375 shares Expires 2030-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:07 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · derivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 3,750 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021. F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.